No Data
No Data
11 Health Care Stocks Moving In Thursday's Intraday Session
Allakos ALLK +48% Merger; CervoMed CRVO +36% Phase 2b Data
CervoMed Shares Are Trading Higher After the Company Announced It Will Present New Data on Neflamapimod's Impact on DLB.
Express News | CervoMed To Present New Data On Neflamapimod's Impact On DLB At 19th International Conference On Alzheimer's and Parkinson's Disease
CervoMed to Present Results on Phase 2b RewinD-LB Study
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia With Lewy Bodies in Oral Presentation at AD/PD 2025